Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment

Journal of Neuroimmunology

Volumn 199, Issue 1-2, 2008, Pages 142-150

  Mazzanti, Benedetta ^a   Aldinucci, Alessandra ^a   Biagioli, Tiziana ^a   Barilaro, Alessandro ^a   Urbani, Serena ^b   Dal Pozzo, Simone ^b   Amato, Maria Pia ^a   Siracusa, Gianfranco ^a   Crescioli, Clara ^a   Manuelli, Cinzia ^a   Bosi, A ^b   Saccardi, Riccardo ^b   Massacesi, Luca ^a   Ballerini, Clara ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Chemokines; Dendritic cells; MS; Stem cells

Indexed keywords

BETA1 INTEGRIN; CD14 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; COMPLEMENTARY DNA; FLUORESCEIN ISOTHIOCYANATE; HERMES ANTIGEN; HLA ANTIGEN; MESSENGER RNA; TOLL LIKE RECEPTOR;

ADULT; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL THERAPY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; MALE; MESENCHYME; MULTIPLE SCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL;

ADULT; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; MULTIPLE SCLEROSIS; PHENOTYPE; RECEPTORS, CYTOKINE; TOLL-LIKE RECEPTORS;

EID: 47549110548     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.05.006     Document Type: Article

References (36)

1. Aggarwal S., and Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005) 1815-1822
2. Baggiolini M., Dewald B., and Moser B. Human chemokines: an update. Ann. Rev. Immunol. 15 (1997) 675-705
3. Bartolomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., Hardy W., Devine S., Ucker D., Deans R., Moseley A., and Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30 (2002) 42-48
4. Beyth S., Borovsky Z., Mevorach D., Liebergall M., Gazit Z., Aslan H., Galun E., and Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105 (2005) 2214-2219
5. Bocelli-Tyndall C., Bracci L., Spagnoli G., Braccini A., Bouchenaki M., Ceredig R., Pistoia V., Martin I., and Tyndall A. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogenic-stimulated lymphocytes in vitro. Rheumatology 4 (2007) 403-408
6. Castro-Malaspina H., Gay R.E., Resnick G., Kapoor N., Meyers P., Chiarieri D., McKenzie S., Broxmeyer H.E., and Moore M.A. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 56 (1980) 289-301
7. Cho H.H., Bae Y.C., and Jung J.S. Role of toll-like receptors on human adipose-derived stromal cells. Stem Cells 24 (2006) 2744-2752
8. Cipriani P., Guiducci S., Miniati I., Cinelli M., Urbani S., Marrelli A., Dolo V., Pavan A., Saccardi R., Tyndall A., Giacomelli R., and Cerinic M.M. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells. Arthritis and Rheum. 56 (2007) 1994-2004
9. Dazzi F., Ramasamy R., Glennie S., Jones S.P., and Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev. 20 (2006) 161-171
10. Deans R.J., and Moseley A. Mesenchymal stem cells: biology and potential clinical uses. Exp. Hematol. 28 (2000) 875-884
11. Gerdoni E., Gallo B., Casazza S., Musio S., Bonanni I., Pedemonte E., Mantegazza R., Frassoni F., Mancardi G., Pedotti R., and Uccelli A. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann. Neurol. 61 (2007) 219-227
12. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D., and Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105 41 (2005) 20-26
13. Koc O.N., Gerson S.L., Cooper B.W., Dyhouse S.M., Haynesworth S.E., Caplan A.I., and Lazarus H.M. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J. Clin. Oncol. 1 (2000) 307-316
14. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., and Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T cells to their cognate peptide. Blood 101 (2003) 3722-3729
15. Krampera M., Pasini A., Pizzolo G., Cosmi L., Romagnani S., and Annunziato F. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr. Opin. Pharmacol. 6 (2006) 435-441
16. Lazarus H.M., Koc O.N., Devine S.M., Curtin P., Maziarz R.T., Holland H.K., Shpall E.J., McCarthy P., Atkinson K., Cooper B.W., Gerson S.L., Laughlin M.J., Loberiza Jr. F.R., Moseley A.B., and Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transpl. 11 (2005) 389-398
17. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., and Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 57 (2003) 11-20
18. Le Blanc K., Rasmusson I., Sundberg B., Götherström C., Hassan M., Uzunel M., and Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
19. Le Blanc K., and Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol. Blood and Marrow Transpl. 11 (2005) 321-334
20. Meisel R., Zibert A., Laryea M., Göbel U., Däubener W., and Dillo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (2004) 4619-4621
21. Nauta A.J., Kruisselbrink A.B., Lurvink E., Willemze R., and Fibbe W.E. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J. Immunol. 177 (2006) 2080-2087
22. Pevsner-Fischer M., Morad V., Cohen-Sfady M., Rousso-Noori L., Zanin-Zhorov A., Cohen S., Cohen I.R., and Zipori D. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109 (2007) 1422-1432
23. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonett D.W., Craig S., and Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
24. Poncelet A.J., Vercruysse J., Saliez A., and Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplant 83 (2007) 783-789
25. Ramasamy R., Fazekasova H., Lam E.W.F., Soeiro I., Lombardi G., and Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into cell cycle. Transplant 83 (2007) 71-76
26. Rasmussen I., Ringden O., Sundberg B., and Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp. Cell Res. 305 (2005) 33-41
27. Saccardi R., Kozak T., Bocelli-Tyndall C., Fassas A., Kazis A., Havrdova E., Carreras E., Saiz A., Löwenberg B., te Boekhorst P.A., Gualandio F., Openshaw H., Longo G., Pagliai F., Massacesi L., Deconink E., Ouyang J., Nagore F.J., Besalduch J., Lisukov I.A., Bonini A., Merelli E., Slavino S., Gratwohl A., Passweg J., Tyndall A., Steck A.J., Andolina M., Capobianco M., Martin J.L., Lugaresi A., Meucci G., Sáez R.A., Clark R.E., Fernandez M.N., Fouillard L., Herstenstein B., Koza V., Cocco E., Baurmann H., Mancardi G.L., and Autoimmune Diseases Working Party of EBMT. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult. Scler. 12 (2006) 814-823
28. Sallusto F., Cella M., Danieli C., and Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182 (1995) 389-400
29. Sorensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik A.V., Qin S., Rottman J., Sellebjerg F., Strieter R.M., Frederiksen J.L., and Ransohoff R.M. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103 (1999) 807-815
30. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., and Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transpl. 75 (2003) 389-397
31. Uccelli A., Zappia E., Benvenuto F., Frassoni F., and Mancardi G. Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. Expert. Opin. Biol. Therap 6 (2006) 17-22
32. Uccelli A., Pistoia V., and Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Imm. 28 (2007) 219-226
33. Urbani S., Caporale R., Bombardini L., Bosi A., and Saccardi R. Use of CFDA-SE for evaluating the in vitro proliferation pattern of human mesenchymal stem cells. Cytotherapy 8 (2006) 243-253
34. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., Mancardi G., and Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducine T-cell anergy. Blood 106 (2005) 1755-1761
35. Zhang W., Ge W., Li C., You S., Liao L., Han Q., Deng W., and Zhao R.C. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 13 (2004) 263-271
36. Zhang J., Li Y., Chen J., Cui Y., Lu M., Elias S.B., Mitchell J.B., Hammill L., Canguri P., and Chopp M. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp. Neurol 195 (2005) 16-26